HLS Therapeutics Inc. Financials

Market Capitalization C$112.9 Million as of Jan. 1, 2025

Valuations Metrics as of May. 5, 2024

Trailing PE	-5.59
Forward PE	-11.34
Price to Sales TTM	C$2.35
Price to Book MRQ	C$1.52
Enterprise to Revenue	3.39
Enterprise to EBITDA	9.95

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	-43.65%
Operating Margin	-6.97%
Return on Assets TTM	-2.87%
Return on Equity TTM	-24.69%

Income Statement

Revenue TTM	C$86,206,389
Revenue per Share TTM	C$1.96
Quarterly Revenue Growth	1.20%
Gross Profit TTM	C$55,450,000
EBITDA	C$21,940,000
Net Income to Common TTM	C$-37,627,994
Diluted EPS TTM	C$-1.16
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	C$30,002,895
Total Cash per Share MRQ	C$0.69
Total Debt MRQ	C$
Total Debt to Equity MRQ	89.69
Current Ratio MRQ	1.65
Book Value per Share MRQ	C$3.06

Cash Flow

Operating Cash Flow TTM	C$21,579,615
Levered Free Cash Flow TTM	C$33,772,906

HLS Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	31,886,200
Float Shares	16,355,860
Avg 10 Volume	2,250
Avg 30 Volume	None
Shares Short	73,669
Short Ratio	4.60
Short % of Shares	%
% Held by Insiders	0.49%
% Held by Institutions	59.69%

Stock Price Summary

Beta	1.14
Fifty Two Week Low	C$3.34
Fifty Two Week High	C$7.12
Fifty Two Week Change	-11.16%
Day 50 MA	C$4.33
Day 200 MA	C$4.53

Dividends and Splits

Forward Annual Dividend Rate	C$0.20
Forward Annual Dividend Yield	4.21%
Trailing Annual Dividend Rate	C$0.08
Trailing Annual Dividend Yield	1.63%
Payout Ratio	0.00%
Dividend Date	2023-06-15
Ex Dividend Date	2023-04-27
Last Split Factor
Last Split Date